recombinant AAV vector development

Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in a virtual mode that is pursuing biologically-based, disease-modifying therapeutic solutions for neurodegenerative disorders known as tauopathies, including Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy, progressive supranuclear palsy, and corticobasal degeneration. INT is advancing monoclonal antibody candidates against key epitopes of Tau toward Phase I clinical trials as prospective passive immunotherapies.

Read more

biotechnology research and developmentmonoclonal antibody developmenttherapeutic development for tauopathies